Hi,

Safety, Ease of preparation on large-scales, Efficacy, Cost effectiveness, and so on must be considered before a dosage form / formulation can enter the market.

The fact is that most applied encapsulation and controlled release protocol are lipid-based carriers.

As a matter of fact, lipidic carriers are the most promising. As a result, majority of the marketed approved nanomedicines are liposomes or lipid-based carriers. These include : Abelcet® , AmBisome® , Amphotec® , DaunoXome® , Diprivan® , DepoCyt® , DepoDur® , Doxil® , Estrasorb® , Fungizone® , Inflexal® V, Marqibo® , Mepact® , Myocet® , Visudyne® , .... as well as some of the main vaccines for SARS-CoV-2 infection.

Thank you sir. I feel that for decreasing the side effects of drugs and save kidney, we need to promote individual dose based microspheres.